M. Martinho

发表

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.

M. Seiberling, I. Savant, G. Krishna, 2009, Clinical therapeutics.

Pharmacokinetic Interactions Between the Fixed‐Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult Participants

M. Rizk, D. Panebianco, M. Iwamoto, 2019, Clinical pharmacology in drug development.

Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct‐Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse‐Transcriptase Inhibitor Tenofovir Disoproxil Fumarate

P. Jumes, J. Butterton, D. Panebianco, 2019, Clinical pharmacology in drug development.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Effect of tildrakizumab (MK‐3222), a high affinity, selective anti‐IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis

M. Iwamoto, M. Martinho, P. Shaw, 2018, British journal of clinical pharmacology.

Effects of oral posaconazole on the pharmacokinetics of sirolimus

M. Seiberling, G. Krishna, M. Martinho, 2009, Current medical research and opinion.

Posaconazole Plasma Concentrations in Juvenile Patients with Invasive Fungal Infection

G. Krishna, M. Martinho, B. Kantesaria, 2007, Antimicrobial Agents and Chemotherapy.

A new solid oral tablet formulation of posaconazole: a randomized clinical trial to investigate rising single- and multiple-dose pharmacokinetics and safety in healthy volunteers

R. Preston, E. O'Mara, G. Krishna, 2012, The Journal of antimicrobial chemotherapy.

Single-Dose Phase I Study To Evaluate the Pharmacokinetics of Posaconazole in New Tablet and Capsule Formulations Relative to Oral Suspension

E. O'Mara, G. Krishna, M. Martinho, 2012, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics and Safety of Oral Posaconazole in Neutropenic Stem Cell Transplant Recipients

E. Anaissie, P. Gubbins, S. Penzak, 2006, Antimicrobial Agents and Chemotherapy.

Pharmacokinetics, Safety, and Efficacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection

D. Kontoyiannis, R. Courtney, I. Raad, 2006, Antimicrobial Agents and Chemotherapy.

Disposition of Posaconazole following Single-Dose Oral Administration in Healthy Subjects

R. Courtney, M. Martinho, B. Flannery, 2004, Antimicrobial Agents and Chemotherapy.

A phase 1 pooled PK/PD analysis of bone resorption biomarkers for odanacatib, a Cathepsin K inhibitor

J. McCrea, J. Stone, S. Stoch, 2020, Journal of Pharmacokinetics and Pharmacodynamics.

Pharmacokinetics of Oral Posaconazole in Neutropenic Patients Receiving Chemotherapy for Acute Myelogenous Leukemia or Myelodysplastic Syndrome

O. Cornely, G. Krishna, M. Martinho, 2008, Pharmacotherapy.

Pharmacokinetics, Safety, and Efﬁcacy of Posaconazole in Patients with Persistent Febrile Neutropenia or Refractory Invasive Fungal Infection

D. Kontoyiannis, R. Courtney, I. Raad, 2006 .

Skin Concentrations and Pharmacokinetics of Posaconazole after Oral Administration

A. Tavakkol, G. Krishna, M. Martinho, 2010, Antimicrobial Agents and Chemotherapy.

Effects of Oral Posaconazole on the Pharmacokinetics of Atazanavir Alone and With Ritonavir or With Efavirenz in Healthy Adult Volunteers

M. Seiberling, G. Krishna, M. Martinho, 2009, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Oral Posaconazole in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft‐versus‐Host Disease

P. Chandrasekar, A. Ullmann, G. Krishna, 2007, Pharmacotherapy.

Posaconazole Pharmacokinetics, Safety, and Tolerability in Subjects With Varying Degrees of Chronic Renal Disease

S. Swan, W. Smith, T. Marbury, 2005, Journal of clinical pharmacology.

Determination of Posaconazole Levels in Toenails of Adults with Onychomycosis following Oral Treatment with Four Regimens of Posaconazole for 12 or 24 Weeks

A. Tavakkol, G. Krishna, M. Martinho, 2011, Antimicrobial Agents and Chemotherapy.

Phase 1b/3 Pharmacokinetics and Safety Study of Intravenous Posaconazole in Adult Asian Participants at High Risk for Invasive Fungal Infections

C. Wang, Depei Wu, X. Ke, 2022, Advances in Therapy.

Effect of Oral Posaconazole on the Pharmacokinetics of Cyclosporine and Tacrolimus

S. Gelone, G. Krishna, M. Martinho, 2007, Pharmacotherapy.

Assessment of The Pharmacokinetic (PK), Pharmacodynamic (PD) Interaction Potential Between Posaconazole and Glipizide in Healthy Volunteers

R. Courtney, P. Statkevich, M. Martinho, 2003 .

Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers

Gopal Krishna, Edward O'Mara, E. O'Mara, 2012, Expert opinion on drug metabolism & toxicology.

Pharmacokinetic Interactions between the Hepatitis C Virus Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, and Darunavir in Healthy Volunteers

X. Chu, P. Jumes, J. Butterton, 2019, Antimicrobial Agents and Chemotherapy.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Buprenorphine/Naloxone in Healthy Participants and Participants Receiving Stable Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

Effects of oral posaconazole on the pharmacokinetics of sirolimus.

M. Seiberling, G. Krishna, M. Martinho, 2009, Current medical research and opinion.

No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist Therapy

L. Webster, P. Jumes, J. Butterton, 2018, Clinical and translational science.

Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin

D. Cutler, T. Kosoglou, P. Statkevich, 2012, European Journal of Clinical Pharmacology.

Pharmacokinetic Interactions Between the HCV Inhibitors Elbasvir and Grazoprevir and HIV Protease Inhibitors Ritonavir, Atazanavir, Lopinavir, or Darunavir in Healthy Participants

X. Chu, P. Jumes, J. Butterton, 2019 .

The Absence of a Clinically Significant Effect of Food on the Single Dose Pharmacokinetics of Vorapaxar, a PAR‐1 Antagonist, in Healthy Adult Subjects

T. Kosoglou, P. Statkevich, M. Martinho, 2013, Clinical pharmacology in drug development.